In the Study of Tirzepatide in Participants with Heart Failure with Preserved Ejection Fraction with Obesity (SUMMIT) trial, tirzepatide significantly reduced the risk of death from cardiovascular causes or worsening heart failure events in patients with heart failure with preserved ejection fraction (ejection fraction 50% and above) and obesity (BMI 30 kg/m 2 ), compared with placebo (HR 0.62
Unifying plant complex: balances the pigmentation of the skin and thus gives unity, harmony and radiance to the complexion
The GLP-1 receptor is widely distributed on the pancreatic, lungs, kidneys, central nervous system, cardiovascular system, gastrointestinal tract, skin, and the vagus nerves
Supports long-term weight loss In the STEP 1 trial, participants taking semaglutide lost an average of almost 15% of their body weight compared to about 2% in the placebo group